Artios Pharma
Latest round
- —
Last raised
- Nov 2026
Total raised
- $502M
Investors
- 28
About Artios Pharma
Based in Cambridge, UK, and founded in 2016, Artios Pharma Limited is a developer of novel cancer treatments designed to target DNA Damage Response (DDR). Michael T. Andriole is the current CEO. The company's medications center on creating treatments through deoxyribonucleic corrosive harm reaction (DDR) pathways to assist changes to their DNA so that it can advance, empowering doctors to specifically slaughter cancer cells through a concept known as manufactured lethality.
Who invested in Artios Pharma
28 investors across 5 rounds
See all investors in Artios Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Artios Pharma
Who invested in Artios Pharma?
Artios Pharma has 28 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Artios Pharma raised?
Artios Pharma has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
What does Artios Pharma do?
Based in Cambridge, UK, and founded in 2016, Artios Pharma Limited is a developer of novel cancer treatments designed to target DNA Damage Response (DDR).
Where is Artios Pharma headquartered?
Artios Pharma is headquartered in Cambridge, UK.
Which VCs invest in companies like Artios Pharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Artios Pharma's stage. Their profiles are linked below.
VCs backing biotechnology startups
Raising like Artios Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.